-
1 Comment
Suzhou Zelgen Biopharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 4854.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 477.2.
Based on the above factors, Suzhou Zelgen Biopharmaceuticals Co., Ltd gets an overall score of 0/5.
| ISIN | CNE100003RP1 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHG |
| CurrencyCode | CNY |
| Market Cap | 27B |
|---|---|
| PE Ratio | None |
| Target Price | 58 |
| Beta | 0.47 |
| Dividend Yield | None |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688266.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
